Slide 1: Investor Presentation 1H2023 results
INVESTOR PRESENTATION 1H2023 results WARSAW // 21.09.2023
Slide 2: Disclaimer
Neither this presentation (the “Presentation”, references to which shall be deemed to include any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further enquiries) nor any copy of it nor the information contained herein is being is
Slide 3: Pharma Financials
PHARMA FINANCIALS
Slide 4: Segment dynamics - FY 2023/2022
Segment dynamics - FY 2023/2022 All amounts in million PLN Well balanced business model with growing R&D costs INNOVATIVE PRODUCTS (R&D) TOTAL BRANDED GENERICS R&D .
Slide 5: Group and Segment P&L Details for 1H2023/1H2022
Group and Segment P&L Details for 1H2023/ 1H2022. 5
Slide 6: Balance sheet
Balance sheet. A. Increase in property, plant and equipment as at 30Jun23 compared to 31Dec22 is related to intense CAPEX that the Company has been incurring for the last 3 years. B. Expansion of IP rights for our legacy business division, contracted in 2020 C. Equity stakes in other companies (Mabi
Slide 7: New CFO – operational challenges 2023/2024
New CFO – operational challenges 2023/2024 Supporting all business development processes in the Company in both, innovative and generic business segment; Preparing further applications for funding Company’s research and development projects under the new FENG perspective implemented by NCBiR, includ
Slide 8: Branded Generics
PHARMA BRANDED GENERICS
Slide 9: Revenues 1H2022-1H2023
Revenues 1H2022-1H2023 +15 112,3 100 94,8 68,4 Q2 2023 Q2 2022 +2 +1 52,8 Q1 2023 Q1 2022 43,9 41,9 (MLN PLN) 0 H12022 Domestic Export Grants H12023 sales
Slide 10: Robust market position of key promoted products in Poland 1H2022/1H2023
Roboust market position of key promoted products in Poland 1H2022/1H2023 16,0% 15,1% 15,2% 14,0% 12,0% 10,0% 8,0% 8,2% 2,8 mln 8,0% 6,2% 6,0% 4,9% 4,0% 2,0% 1,7% 1,8% 1H2022 2H2023 1H2022 2H2023 1H2022 2H2023 1H2022 2H2023 0,0% Salmex Ketrel Valzek Donepex % MS/IQVIA 06.2022-062023
Slide 11: Innovative Business
PHARMA ININIOW NENA BUSINESS
Slide 12: News Flow & Key Milestones 2023/2024
News Flow & Key Milestones 2023/2024 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 CPL’280 end of Phase 2 in diabates CPL’36 end of Phase 2 in both indications CPL’116 end of Phase 2 in RA CPL’116 CPL’280 end of Phase 2 in RA start of Phase 2b in diabetes CPL’280 start of Phase 2 in diabetes Metabolic dis
Slide 13: Partnering Strategy 2023/2024
Partnering Strategy 2023/2024 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 FALKIERI CPL’ 280 CPL’36 CPL’116 CPL’110 Metabolic diseases Oncology Neuropsychiatry Inflamatory diseases
Slide 14: Scientific activities & conferences
Scientific activities & conferences Q3 2023 Q4 2023 Q1 2024 CPL976, an innovative bispecific antibody targeting AXL and PD-L1 axis as a potential new anticancer therapeutic Design and preclinical evaluation of CPL976-MMAE - novel, potent AXL-PD-L1 bispecificantibody conjugated with MMAE in targeted
Slide 15: QA
QA